Utama › Kanser Kolorektal › Wisconsin › Madison
Kajian klinikal Kanser Kolorektal di Madison, WI
23 kajian untuk Kanser Kolorektal sedang mencari peserta di lokasi dalam dan sekitar Madison (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
Mengambil pesertaFasa 2
- University of Wisconsin, Madison
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Mengambil pesertaFasa 1/2
- University of Wisconsin Carbone Cancer Center, Madison
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Mengambil pesertaFasa 2
- UW Health Carbone Cancer Center, Madison
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- William S Middleton VA Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Mengambil pesertaFasa 1
- Wisconsin Institute for Medical Research, Madison
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Mengambil pesertaFasa 1/2
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Mengambil pesertaFasa 1/2
- University Hospital and UW Health Clinics-Carbone Cancer Center ( Site 0293), Madison
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Mengambil pesertaFasa 3
- William S. Middleton Memorial VA, Madison
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Mengambil pesertaFasa 3
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Mengambil pesertaFasa 2
- Research Site, Madison
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Mengambil pesertaFasa 1
- University of Wisconsin - Carbone Cancer Center, Madison
Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
Mengambil pesertaFasa 2
- University of Wisconsin Carbone Cancer Center, Madison
An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis
Mengambil pesertaFasa 2
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Mengambil pesertaFasa 3
- Clinical Study Site, Madison
A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)
Mengambil pesertaFasa 1
- Univ of Wisconsin-Madison, Madison
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Mengambil pesertaFasa 1
- University of Wisconsin - Carbone Cancer Center, Madison
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Mengambil pesertaFasa 1/2
- University of Wisconsin, Carbone Cancer Center, Madison
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- University of Wisconsin- Madison, Madison
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
Mengambil pesertaFasa 1/2
- GSK Investigational Site, Madison
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Mengambil pesertaFasa 1/2
- University of Wisconsin, Madison
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Mengambil pesertaFasa 1
- University of Wisconsin (Carbone Cancer Center), Madison
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Mengambil pesertaKajian pemerhatian
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Mengambil pesertaFasa 4
- University of Wisconsin, Madison
Kajian Kanser Kolorektal di bandar lain
- Houston, TX102 kajian
- New York City, NY78 kajian
- Nashville, TN69 kajian
- Boston, MA63 kajian
- Los Angeles, CA59 kajian
- Arlington, VA52 kajian
- St. Louis, MO50 kajian
- San Antonio, TX46 kajian
- Philadelphia, PA44 kajian
- Grand Rapids, MI40 kajian
- Baldwin Park, CA37 kajian
- Chicago, IL34 kajian
Kajian lain di Madison
- Kanser Prostat29 kajian
- Kanser Payudara22 kajian
- Kanser Metastatik21 kajian
- Leukemia Mieloid Akut16 kajian
- Kanser Paru-paru Bukan Sel Kecil16 kajian
- Melanoma15 kajian
- Kanser (semua jenis)14 kajian
- Kanser Ovari13 kajian
- Kanser Perut11 kajian
- Kanser Pankreas10 kajian
- Kanser Paru-paru10 kajian
- Mieloma Pelbagai9 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.